#ASCOGU2024 Archives

ASCO-GU Interview | Dr. Pengfei Shen Interprets PROpel Study, Shares Genetic Testing to Guide Precise Treatment of Prostate Cancer

By Mourabit Halima 2024.03.04

Editor's Note: Following the breakthrough of the PROfound study, which marked the beginning of precision treatment for prostate cancer, the PROpel study has further extended the application of PARP inhibitors…

ASCO-GU Interview | Dr. Fufu Zheng Shares Advances in First-Line PARPi Treatment and Genetic Testing for mCRPC

By Mourabit Halima 2024.03.04

Editor's note: At the 2024 American Society of Clinical Oncology Genitourinary Cancers Symposium (ASCO-GU 2024) held recently, data on patients with homologous recombination repair mutations (HRRm) from the PROpel study…

Insights from ASCO GU: An Exclusive Interview with UBC’s Marie-Pier St-Laurent | Oncology Frontier

By Mourabit Halima 2024.01.31

Welcome to a special feature by Oncology Frontier, where we bridge the gap between continents in the realm of medical innovation. Today, we're honored to host Marie-Pier St-Laurent from the University of British Columbia. As part of our exclusive Specialist Interview series, Marie-Pier will be sharing valuable insights from her recent abstract presented at ASCO GU. Stay tuned as we delve into groundbreaking research that's shaping the future of oncological care. Visit us at www.ioncol.com for more thought-provoking content